Charles Duncan Analyst Performance

Managing Director & Senior Research Analyst at Cantor Fitzgerald

Charles Duncan is a stock analyst at Cantor Fitzgerald focused in the medical sector, covering 46 publicly traded companies. Over the past year, Charles Duncan has issued 6 stock ratings, including buy and hold recommendations. While full access to Charles Duncan's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Charles Duncan's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

297 Last 10 Years

Buy Recommendations

85.86% 249 Buy Ratings

Companies Covered

46 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.3%	1 ratings
Buy	85.5%	248 ratings
Hold	13.8%	40 ratings
Sell	0.3%	1 ratings

Out of 290 total stock ratings issued by Charles Duncan at Cantor Fitzgerald, the majority (85.5%) have been Buy recommendations, followed by 13.8% Hold, 0.3% Strong Buy, and 0.3% Sell.

Best & Worst Calls

• Best Call

  000000.0%

  AXSM

  Dec 2018

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  ARGSQ

  Jun 2016

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	91.3% of companies on NASDAQ	42 companies
OTCMKTS	4.3% of companies on OTCMKTS	2 companies
TSE	2.2% of companies on TSE	1 company
NYSE	2.2% of companies on NYSE	1 company

Charles Duncan, an analyst at Cantor Fitzgerald, currently covers 46 companies listed on NASDAQ, OTCMKTS, TSE and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 42 companies	91.3%
	Miscellaneous 3 companies	6.5%
	Aerospace 1 company	2.2%

Charles Duncan of Cantor Fitzgerald specializes in stock coverage within the Medical sector, with additional focus on and Aerospace companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 18 companies	39.1%
PHARMACEUTICAL PREPARATIONS 16 companies	34.8%
MED - DRUGS 5 companies	10.9%
Miscellaneous 3 companies	6.5%
MEDICAL SERVICES 1 company	2.2%
DRUG MANUFACTURERS - SPECIALTY & GENERIC 1 company	2.2%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	2.2%
AEROSP/DEF EQ 1 company	2.2%

About Charles Duncan

Charles has >25 years of sell-side experience, and is a Managing Director and senior biotechnology research analyst at Cantor Fitzgerald. From late 2012 and until early July 2018 he was a Managing Director and senior biotech analyst at Piper Jaffray & Co. Previously he was a founding partner of JMP Securities healthcare group and served as an analyst with that firm since 2002. He has also been a publishing analyst at Dresdner Kleinwort Wasserstein, Vector Healthcare Group - Prudential Securities, Tucker Anthony Cleary Gull and Chatfield Dean & Co. Duncan has been recognized by industry sources, including the StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis. Additionally Charles has achieved Tip Ranks ranking that places him in the top 5% of all analysts and above the majority of other senior biotech analysts.

Follow on LinkedIn

Charles Duncan's Ratings History at Cantor Fitzgerald

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
SLDB Solid Biosciences	7/21/2025	Set Price Target	$6.73	$16.00	Overweight	$0.00 00.00% ROI
CMPS COMPASS Pathways	3/28/2025	Reiterated Rating	$3.03		Overweight	$0.00 00.00% ROI
ACAD ACADIA Pharmaceuticals	2/27/2025	Reiterated Rating	$20.24	$28.00	Overweight	$0.00 00.00% ROI
JAZZ Jazz Pharmaceuticals	2/26/2025	Downgrade	$144.60	$150.00	Neutral	$0.00 00.00% ROI
AXSM Axsome Therapeutics	2/19/2025	Reiterated Rating	$127.42	$153.00	Overweight	$0.00 00.00% ROI
GHRS GH Research	2/13/2025	Initiated Coverage	$14.00	$14.00	Overweight	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.